PCM
PBE icon

Peak Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Peak Capital Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-196
Closed -$10K – 185
2018
Q1 		$10K Buy
+196
New +$10K 0.01% 45

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
CAS
Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Peak Capital Management's PBE Position: Q2 2018 in Review

Peak Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2018, closing a stake of 196 shares — an estimated $10K sold.

Peak Capital Management first reported a position in PBE in Q1 2018 and held it in 1 quarter. The position peaked at $10K in Q1 2018. 73 funds tracked by Wall St. Rank hold PBE as of Q2 2018.

  • Peak Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2018 after selling out during the quarter.
  • Peak Capital Management sold 196 Invesco Biotechnology & Genome ETF shares in Q2 2018, an estimated $10K.
  • Peak Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2018 and held it in 1 quarter.
  • Peak Capital Management's Invesco Biotechnology & Genome ETF position peaked at $10K in Q1 2018.
  • 73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2018.

Based on Peak Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.